Pieter Droppert writes the Biotech Strategy Blog "The Street" and is a marketing strategy consultant with a focus on oncology/hematology new product development.
In his blog "Winners And Losers in CLL at ASCO '13", he writes:
"New products in development for chronic lymphocytic leukemia (CLL), an incurable B-cell cancer, will transform the treatment of this disease over the next few years.
CLL offers a big market opportunity as more than 150,000 people in the U.S. and Europe have the disease, and about a third of these require first or second-line therapy."
He covers in particular how the new drugs by Gilead Sciences (idelalisib), Roche (Obinutuzumab - GA101), Infinity Pharmaceuticals (IPI-145), AbbVie (with Roche) (ABT-199), Pharmacyclics and Johnson & Johnson (Ibrutinib) fared in their ASCO presentations and which companies with CLL drug development in the pipeline were absent from ASCO.
More:
thestreet.com/story/1194443...
Neil
Ibrutinib Slow but steady foreward movement.
ibrutinib, opposite effect.
Are there possibilities other than stem cell transplant in Canada for CLL with 11Q deletion?
